Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access

This article was originally published in The Pink Sheet Daily

Executive Summary

Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.

You may also be interested in...



Political Appointees Shouldn't Influence Approval Decisions, Califf Says

FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.

FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide

Keeping guidances in draft form makes Congress angry, but finalizing them gives Wall Street the vapors.

Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community

Is the lack of rejection cause for optimism, or will eteplirsen end up like BioMarin's drisapersen?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel